Abstracts tagged "PD-1"

Abstract Number: 1515 • ACR Convergence 2021
Programmed Cell Death Protein 1 (PD-1)-Expressing CD4+ T Cells Are Expanded in Early Rheumatoid Arthritis and Correlate with Response to Treatment
Katie Williams¹, Annabelle Small², Qingxuan Song³, Suzanne Cole⁴, Ling-yang hao⁵, William Murray-Brown⁶, Susanna Proudman⁷, Malcolm Smith⁸, Sunil Nagpal⁹ and Mihir Wechalekar¹⁰, ¹Flinders University, Adelaide, Australia, ²Flinders University, Bedford Park, Australia, ³Janssen Research & Development LLC, Spring House, PA, ⁴Janssen Research, Adelaide, Australia, ⁵Janssen Research, Philadelphia, PA, ⁶GlaxoSmithKline, Adelaide, Australia, ⁷University of Adelaide, Medindie, Australia, ⁸Flinders Medical Centre, Adelaide, Australia, ⁹Janssen Research, Collegeville, PA, ¹⁰Flinders Medical Centre, Bedford Park, Australia
Background/Purpose: Programmed death protein 1 (PD-1) expressing T cells, including T follicular and T peripheral helper cells, are expanded in the circulation of individuals with…
Abstract Number: 99 • 2019 ACR/ARP Annual Meeting
Mass Cytometry Immunophenotyping of Synovial Fluid from Checkpoint Inhibitor Related Arthritis
Runci Wang¹, Karmela Kim Chan ², Amy Cunningham-Bussel ³, Laura Donlin ⁴, Gregory Vitone ², Aidan Tirpack ², Caroline Benson ², Gregory Keras ³, Anna Helena Jonsson ⁵, Michael Brenner ⁶, Anne Bass ⁷ and Deepak Rao ¹, ¹Brigham and women's hospital, Boston, MA, ²Hospital For Special Surgery, New York, ³Brigham and women's hospital, Boston, ⁴Hospital For Special Surgery, New York, NY, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Brigham and Women’s Hospital:, Boston, ⁷Hospital for Special Surgery/Weill Cornell Medicine, New York, NY
Background/Purpose: Anti-PD-1/PD-L1 checkpoint inhibitor therapies have produced remarkable results in stimulating immune responses against tumors. Checkpoint inhibitor therapy can also trigger a variety of autoimmune…
Abstract Number: 1809 • 2019 ACR/ARP Annual Meeting
A Quarter of Patients Treated with Checkpoint Inhibitors Develop Immune-Related Adverse Events: A University Center Experience
Celine Zhou ¹, Whitney Elg-Salsman¹, Sonam Kiwalkar ², Nishad Sathe ¹, Marcia Friedman ¹ and Atul Deodhar ², ¹Oregon Health and Science University, Portland, OR, ²Oregon Health & Science University, Portland, OR
Background/Purpose: Immune checkpoint inhibitors (ICIs) are increasingly becoming the mainstay of management of advanced malignancies, but can result in immune related adverse events (irAEs) affecting…
Abstract Number: 150 • 2018 ACR/ARHP Annual Meeting
PD-1 Signaling Interferes with OX40L to Alter the Suppressive Function and Proliferation of CD4+ Regulatory T Cells in Lupus Mice
Maida Wong¹ and Bevra H Hahn², ¹Division of Rheumatology, Tibor Rubin Veterans Affairs Medical Center Long Beach, Long Beach, CA, ²Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: In systemic lupus erythematosus (SLE), the dysregulated production of autoantibodies is a consequence of disrupted T cell homeostasis. Programmed death-1 (PD-1), a negative regulator…
Abstract Number: 351 • 2018 ACR/ARHP Annual Meeting
Rheumatic Immune-Related Adverse Events in Patients on ANTI-PD-1 Inhibitors: Fasciitis with Myositis Syndrome As a New Rheumatic Complication of Immunotherapy
Francisco Javier Narváez¹, Pablo Juárez², Judit Lluch², Jose Antonio Narvaez³, Ramón Palmero⁴, Xavier Garcia del Muro⁴, Joan Miquel Nolla² and Eva Domingo-Domenech⁵, ¹Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ²Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Radiology, Hospital Universitari de Bellvitge, Barcelona, Spain, ⁴Medical Oncology., Institut Català d'Oncologia. Hospital Duran i Reynals., Barcelona, Spain, ⁵Hematology, Institut Català d'Oncologia. Hospital Duran i Reynals, Barcelona, Spain
Background/Purpose: To evaluate the prevalence and type of rheumatic immune-related adverse events (IRAEs) in patients receiving programmed cell death protein-1 (PD-1) inhibitors. Methods: This is…
Abstract Number: 357 • 2018 ACR/ARHP Annual Meeting
Musculoskeletal Immune-Related Adverse Events with Use of Checkpoint Inhibitors in Malignancy: Experience in Sydney, Australia
Abhishikta Dey^1,2, Nicholas Manolios^3,4, Georgina Long^4,5,6, Richard Kefford^3,4,5,7 and Leslie Schrieber^8,9, ¹Pain Medicine, Royal Prince Alfred Hospital, Camperdown, Australia, ²Royal North Shore Hospital, North Sydney, Australia, ³Westmead Hospital, Sydney, Australia, ⁴University of Sydney, Sydney, Australia, ⁵Melanoma Institute Australia, North Sydney, Australia, ⁶Royal North Shore Hospital, St Leonards, Australia, ⁷Macquarie University Hospital, Sydney, Australia, ⁸Royal North Shore Hospital, St Leonards, Sydney, Australia, ⁹Northern Clinical School, University of Sydney, Sydney, Australia
Background/Purpose: The strategy of using monoclonal antibodies to inhibit checkpoints on T cells, and enhance T-cell activity against cancer cells has significantly improved the survival…
Abstract Number: 361 • 2018 ACR/ARHP Annual Meeting
Risk Factors of Immune-Related Adverse Events in Patients Treated with Anti-Programmed Cell Death 1 Antibody Pembrolizumab
In Young Kim¹, Yeonghee Eun¹, Hyungjin Kim¹, Joong Kyong Ahn², Eun-Jung Park³, Chan Hong Jeon⁴, Jinseok Kim⁵, Hoon-Suk Cha¹, Eun-Mi Koh¹ and Jaejoon Lee¹, ¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), ²Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), ³Department of Medicine, National Medical Center, Seoul, Korea, Republic of (South), ⁴Department of Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea, Republic of (South), ⁵Department of Medicine, Jeju National University Hospital, University of Jeju School of Medicine, Jeju, Korea, Republic of (South)
Background/Purpose: Immune checkpoint inhibitors have been established as a novel standard treatment for various types of malignancies. However, these new class of drugs have led…
Abstract Number: 2459 • 2018 ACR/ARHP Annual Meeting
Nivolumab-Induced Synovial Tissue T Cell Infiltration, Sustained PD1 Occupancy and Resolution of Severe Synovitis with Infliximab Therapy
William Murray-Brown¹, Helen Weedon¹, Tom Wilsdon², Susanna Proudman³, Jenny Walker¹, Malcolm D. Smith⁴ and Mihir D Wechalekar^1,5, ¹Rheumatology, Flinders University, Adelaide, Australia, ²Rheumatology, Flinders Medical Centre, Adelaide, Australia, ³Royal Adelaide Hospital, Rheumatology Unit and University of Adelaide, Discipline of Medicine, Adelaide, Australia, ⁴Rheumotology, Flinders University, Adelaide, Australia, ⁵Royal Adelaide Hospital, Adelaide, Australia
Background/Purpose: Checkpoint inhibitors (CI) for cancer therapy are associated with inflammation that can recapitulate features of autoimmunity, including synovitis resembling rheumatoid arthritis (RA). No reports…
Abstract Number: 2797 • 2018 ACR/ARHP Annual Meeting
Regulation of Autoimmune T Cells By the Co-Receptors CD28 and PD-1
Sabina Sandigursky¹ and Adam Mor², ¹Medicine, NYU School of Medicine, New York, NY, ²Rheumatology and Pathology, NYU School of Medicine, New York, NY
Background/Purpose: T cells play a major role in the pathogenesis of Rheumatoid Arthritis (RA). These cells are regulated by signals provided via the T cell…
Abstract Number: 2095 • 2017 ACR/ARHP Annual Meeting
Traditional Disease Modifying Anti-Rheumatic Drugs (tDMARDs), Hydroxychloroquine (HCQ) and/or Sulfasalazine (SSZ), Are Rapidly Effective in Immune Checkpoint Inhibitors-Induced Inflammatory Arthritis
Jessie Alperin¹, Jeffrey Sarazin², Leslie Fecher³, Christopher Lao³, Seetha Monrad⁴, David Fox¹ and Elena Schiopu⁵, ¹University of Michigan Medical System, Ann Arbor, MI, ²Rheumatology, University of Michigan Medical System, Ann Arbor, MI, ³Oncology, University of Michigan Medical System, Ann Arbor, MI, ⁴Internal Medicine/Rheumatology, University of Michigan Medical System, Ann Arbor, MI, ⁵Internal Medicine, University of Michigan Medical System, Ann Arbor, MI
Background/Purpose: Immune checkpoint inhibitor (ICI) therapy is widely used in the treatment of metastatic melanoma and non-small cell lung cancer and it is under investigation…
Abstract Number: 2580 • 2017 ACR/ARHP Annual Meeting
Exploiting Inhibition of PD1 Signaling in a Murine Model of Anti-SSA/Ro Associated Congenital Heart Block
Robert M. Clancy¹, Glenn Fishman¹, Colin Phoon¹, Marc Halushka², Tanisha Jackson¹, Kimberly Robins¹ and Jill P. Buyon¹, ¹NYU School of Medicine, New York, NY, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The most serious manifestation of fetal exposure to maternal anti-Ro antibodies is the development of heart block. This work addresses the hypothesis that fetal…
Abstract Number: 2705 • 2017 ACR/ARHP Annual Meeting
Aberrant Expression and Function of Human Circulating T Follicular Helper Cells and Its Subsets in IgG4 Related Disease
Yu Chen¹, Wen Zhang², Panpan Zhang³, Yanan Zhu¹ and Hongxian Yang³, ¹Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, ²Rheuamtology, Peking Union Medical College Hospital, Beijing, China, ³rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China
Background/Purpose: To study the expression and function of T follicular helper cells and its subsets in IgG4-related disease(IgG4-RD). Methods: Flow cytometry was performed to analyze…
Abstract Number: 1340 • 2016 ACR/ARHP Annual Meeting
Type and Frequency of Immune-Related Adverse Reactions in Patients Treated with Pembrolizumab (Keytruda), a Monoclonal Antibody Directed Against PD-1, in Advanced Melanoma at a Single Institution
Olga Pinkston¹, Florentina Berianu¹ and Benjamin Wang², ¹Rheumatology, Mayo Clinic, Jacksonville, FL, ²Division of Rheumatology, Mayo Clinic, Jacksonville, FL
Background/Purpose: Although immune checkpoint inhibitors improve survival in patients with melanoma and other cancers, the alterations to the immune system induced by these medications can…
Abstract Number: 2925 • 2016 ACR/ARHP Annual Meeting
Programmed Cell Death (PD)-1 May Play a Significant Role in the Pathogenesis of Rheumatoid Arthritis
Sabina Sandigursky¹ and Adam Mor², ¹Medicine, NYU, New York, NY, ²Rheumatology and Pathology, NYU Langone Medical Center, New York, NY
Background/Purpose: PD-1 is a co-inhibitory transmembrane protein with a significant effect on immune regulation. Several studies have shown elevated expression levels of PD-1 on T…
Abstract Number: 3042 • 2016 ACR/ARHP Annual Meeting
PD-1–Expressing T Cells in GCA Fail to Promote Immune Tolerance Functions
Ryu Watanabe¹, Hui Zhang², Ebru Hosgur², Gerald Berry³, Jorg Goronzy⁴ and Cornelia M. Weyand², ¹Medicine: Immunology/Rheumatology, Stanford University School of Medicine, Stanford, CA, ²Medicine: Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ³Pathology, Stanford University School of Medicine, Stanford, CA, ⁴Medicine/Division of Immunology & Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: The vasculitic lesions in GCA are filled with differentiated effector T cells that sustain granuloma formation, vessel wall restructuring, neoangiogenesis and intimal hyperplasia. Persistent…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].